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PMH16
ATYPICAL ANTIPSYCHOTICS IN THE 
TREATMENT OF SCHIZOPHRENIA: ADVERSE 
EVENTS, NON-COMPLIANCE AND COST
Meddis D1, Williams P2
1AstraZeneca, Macclesfield, Cheshire, UK; 2PAREXEL Medical 
Marketing Services, Uxbridge, UK
OBJECTIVE: to estimate the economic impact of non-
compliance associated with two adverse events (weight
change, extrapyramidal symptoms [EPS]) resulting from
treatment of schizophrenia with atypical antipsychotics.
METHODS: Differential adverse event profiles were ex-
pected to cause differences between antipsychotics in
terms of compliance, relapse rate and direct costs. Using
a state-transition model, non-compliance and relapse
over one year following recovery from a schizophrenic
episode were simulated. Three transition probabilities
governed movement between states: WELL, COMPLI-
ANT to RELAPSE, derived from literature on relapse with
atypical antipsychotics; WELL, NON-COMPLIANT to
RELAPSE, derived from a quantitative literature summary
of relapse following antipsychotic withdrawal; WELL,
COMPLIANT to WELL, NON-COMPLIANT, based on
non-compliance estimates from a two-round Delphi study.
Twenty-five experts in the treatment of schizophrenia,
blind to the identity of the products, reviewed published
literature on weight change and EPS liability for olanza-
pine, quetiapine, risperidone and ziprasidone. Respon-
dents assumed them to be identical except for adverse
event liability. Bootstrap estimates of differential relapse
rates between the atypicals were obtained, accounting
for uncertainty in all three transition probabilities. Pub-
lished data on direct costs of relapse were applied, giving
incremental cost estimates for different adverse event lia-
bilities.
RESULTS: Quetiapine and ziprasidone were similar in
estimated non-compliance and relapse rates. Compared
to quetiapine, greater weight change with olanzapine led
to higher estimated non-compliance and incremental one-
year per-patient costs of $530 (95% CI  $275–800,
p  .00001), using USA-based cost data. Greater EPS lia-
bility with risperidone led to higher estimated non-com-
pliance and incremental one-year per-patient costs of
$485 (95% CI  $235–800, p  .00001) compared to
quetiapine. Similar increased costs of treatment with
olanzapine and risperidone were shown (£630 [95% CI 
£330-960] and £575 [95% CI  £280–960] respectively)
when UK-based cost data were used.
CONCLUSIONS: The more favourable adverse event
profile of quetiapine is associated with a predicted de-
crease in one-year per-patient direct costs compared to
olanzapine and risperidone.
PMH17
LONG-TERM ECONOMIC BENEFITS OF 
ANTIPSYCHOTIC USE
Boscoe AN1, White RE1, Bolge SC2
1AstraZeneca, Wilmington, DE, USA; 2Consumer Health 
Sciences, Princeton, NJ, USA
OBJECTIVES: To illustrate the decrease in resource utili-
zation over time among persons with bipolar disorder
treated with antipsychotics.
METHODS: In December 2000, 234 persons reported a
diagnosis of bipolar disorder on a self-administered ques-
tionnaire. Of these, 57 reported currently using an anti-
psychotic: Haldol, Risperdal, Seroquel, and Zyprexa. Re-
spondents using antipsychotics were categorized according
to the number of months on drug: zero to six, and seven or
greater. The treatment-duration groups were compared by
resource use during a six-month period: number of visits
to all outpatient providers, including primary physician,
counselor, gynecologist, neurologist, psychiatrist, psychol-
ogist, and other medical specialists; visits to the emergency
room for mental health reasons; days hospitalized for men-
tal health reasons. Lastly, costs of resources used were cal-
culated based on US Census Bureau, Statistical Abstracts
of the United States, 2000: emergency room costs, $320
per visit; hospitalizations, $1,126 per day; outpatient pro-
vider costs, $85 per visit.
RESULTS: Respondents using antipsychotics for seven
months or longer had fewer visits to outpatient providers
(17.1 versus 30.9, p  0.086), emergency room visits (0.2
versus 0.7, p  0.062) and days of hospitalization (1.6
versus 3.8, p  0.202) than those using an antipsychotic
for six months or less. Among respondents using an an-
tipsychotic for seven months or longer, the average cost
of outpatient resource use ($1453.23 versus $2623.91),
ER visits for mental health reasons ($70.00 versus
$208.70), and hospitalization for mental health reasons
($1816.13 versus $4299.27) are lower than among those
using an antipsychotic for six months or less.
CONCLUSION: Resource utilization, especially hospital-
ization, during the early months of antipsychotic use is
very costly. However, continued use of antipsychotics
leads to a decrease in inpatient and outpatient resource uti-
lization. Therefore, it becomes more cost-effective to main-
tain a patient on antipsychotic medication over time.
PMH18
DEPRESSION AND QUALITY OF LIFE AND 
THEIR EFFECT ON HEALTH-CARE UTILIZATION
Bushnell DM, Martin ML
Health Research Associates Inc (HRA), Seattle, WA
OBJECTIVE: To describe use of health-care resources by
levels of depression and quality of life (QOL).
METHODS: The Longitudinal Investigation of Depres-
sion Outcomes (LIDO) is an observational study measur-
ing depression and its economic and QOL correlates in
patients visiting primary care clinics in six international
cities (Barcelona, Be’er Sheva, Melbourne, Porto Alegre,
St. Petersburg, and Seattle). Health-care utilization was
assessed using an interview-based resource utilization
questionnaire (RUQ) collecting information on the type,
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number and length of health-care visits. For our analysis,
the total time spent with a primary health-care profes-
sional was calculated. Centers for Epidemiologic Studies –
Depression (CES-D, representing symptom-based severity
of depression) and Quality of Life Depression Scale
(QLDS, depression-specific quality of life) data were
gathered from a sample of patients self-reporting depres-
sive symptoms, but not necessarily having a diagnosis of
depression.
RESULTS: Using the cross-sectional baseline measure-
ment point, a total of 2359 patients were evaluated
across the sites. Dividing the population by CES-D scores
(20, 20), all sites except St. Petersburg had a pattern
where those with lower CES-D scores (less depressive
symptomatology) spent less time with their doctors than
those with more moderate to severe depression (ranging
from 1 minute in Barcelona to over 10 minutes in Seat-
tle). Comparing groups split by mean quality of life
scores, a similar pattern was noted with those having
lower quality of life spending less time with their health
care provider (1 minute in Melbourne to 10 minutes in
Seattle).
CONCLUSION: With the exception of the site in St. Pe-
tersburg, primary care patients who self-report depressive
symptoms and lower quality of life tend to spend more
actual contact time with their health-care providers.
PMH19
IDENTIFICATION AND ONE-YEAR COSTS OF 
TREATMENT-RESISTANT DEPRESSION IN A 
CLAIMS DATA ANALYSIS
Corey-Lisle P1, Claxton A1, Birnbaum H2, Marynchenko M2, 
Greenberg P2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group/
Economics, Cambridge, MA, USA
OBJECTIVE: Major depressive disorder (MDD) is a de-
bilitating condition with significant economic conse-
quences. Estimates indicate that up to 30% of individuals
with MDD are treatment resistant (TRD). The study ob-
jectives were (a) evaluation of studying TRD using claims
data; (b) estimation of cost differences between TRD and
non-TRD patients.
METHODS: Data source was administrative claims data
from a Fortune 100 manufacturer. Claims included medi-
cal, pharmaceutical and disability claims for 1996–1998
(n  100,000). The sample was restricted to claims for
MDD (NMDD  4,186). Using a treatment algorithm,
patients were classified into TRD-likely and TRD-unlikely
groups (NTRD  487). Resource utilization was com-
pared between TRD-likely, TRD-unlikely patients, and a
sample of the overall population.
RESULTS: The algorithm classified twelve percent of the
MDD sample as TRD. Average annual costs were $10,954
for TRD-likely patients, $5,025 for TRD-unlikely pa-
tients, and $3006 for average beneficiaries. The average
number of health claims among TRD-likely patients were
one and a half times greater than that of TRD-unlikely
patients.
CONCLUSION: Resource utilization by TRD-likely pa-
tients is substantial, not only for direct treatment of de-
pression but also for treatment of co-morbid medical
conditions. Additionally, TRD imposes substantial indi-
rect costs on employers, primarily resulting from high
rates of depression-associated disability.
PMH20
COMPARISON OF ADVERSE DRUG EVENTS 
(ADE) ASSOCIATED WITH SELECTIVE 
SEROTONIN REUPTAKE INHIBITORS (SSRI) IN 
TWO MANAGED CARE ORGANIZATIONS (MCO)
Rascati KL1, Conner TM2
1The Center for Pharmacoeconomic Studies - The University of 
Texas, Austin, TX, USA; 2Seton Health Network, Austin, TX, USA
OBJECTIVE: To compare Adverse Drug Events (ADE)
associated with Selective Serotonin Reuptake Inhibitors
(SSRI) in two Managed Care Organizations (MCO).
METHODS: Medical records for two MCOs in central
Texas were reviewed. Scott and White Health Plan
(SWHP) is a general health plan and Alamo Mental
Health Group (AMHG) is a behavioral/mental health or-
ganization. Inclusion criteria for both settings were pa-
tients over 18 years old that had a diagnosis of depres-
sion and had a new prescription for an SSRI.
RESULTS: A total of 337 patients in SWHP and 361 pa-
tients in AMHG met the inclusion criteria. About 40%
(N  135) of SWHP patients and 40% (N  144) of
AMHG patients had at least one adverse drug event
(ADE) associated with an SSRI noted in their medical
record. The most common ADEs reported were sleep cy-
cle disturbances, e.g. insomnia, daytime sedation 13(%);
GI disturbances, e.g. diarrhea, nausea/vomiting 11(%);
sexual dysfunction 7(%); and anxiety/nervousness 5(%).
Of those with reported ADEs (N  135  144  279), at
least one therapy change due to ADEs was made for 71%
(N  96) of the SWHP patients and 69% (N  100) of
the AMHG patients: 25% were switched to another anti-
depressant; 20% had a medication added; 19% had a
change in the dose/regimen of their index medication;
12% discontinued their index medication. The most
common medication added to treat side effects at SWHP
was trazodone, while the most common addition at
AMHG was bupropion.
CONCLUSIONS: Although the health-care settings dif-
fered in type (general versus behavioral/mental health), re-
sults were strikingly similar. About 40% of the patients re-
ported ADEs and of these, about 70% had at least one
change made to their therapy, many discontinuing the
original medication. Strategies for treating ADEs appeared
to vary by setting, which may have cost implications. Fu-
ture research might examine the impact of ADE strategies
and patient education on continuity of treatment.
